[Melatonin and bone status].
This paper reviews the findings accumulated on the role of melatonin (MEL) on bone status and the role of RANKL/RANK/OPG system (receptor activator of nuclear factor-kappa B ligand/ receptor activator of nuclear factor-kappa B/osteoprotegerin) in this mechanism. Recent studies indicate that MEL may influence on the bone directly by acting osteoclasts and perhaps osteoblasts, and/or indirectly by down-regulating RANK-mediated osteoclast formation and activation. Induced by MEL, changes in the level of factors which play a role in the regulation of bone remodelling, may secondarily (directly and/or indirectly through RANKURANK/OPG system) influence on bone status.
Ostrowska
Zofia
Z
Slaska Akademia Medyczna w Katowicach, Zakfad Biochemii Klinicznej.
Wołkowska-Pokrywa
Kinga
K
Kos-Kudła
Beata
B
Swietochowska
Elzbieta
E
Marek
Bogdan
B
Kajdaniuk
Dariusz
D
D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001862:Bone Resorption / Q000378:metabolism* / Q000503:physiopathology; D001842:Bone and Bones / Q000378:metabolism; D005260:Female; D006801:Humans; D008550:Melatonin / Q000494:pharmacology / Q000502:physiology*; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology*; D010024:Osteoporosis / Q000378:metabolism*; D010870:Pineal Gland / Q000502:physiology; D053245:RANK Ligand / Q000378:metabolism; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000378:metabolism
D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D008550:Melatonin